>Q4 2017 Financial Results

**SALES WORLDWIDE**

*ON COMPARABLE OPERATIONAL BASIS*

+7.7%  

*ON REPORTABLE BASIS*

+42.3%  

---

**Strong Performance in CORE BUSINESS SEGMENTS**

**SALES ON COMPARABLE OPERATIONAL BASIS**

<table>
<thead>
<tr>
<th>Segment</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIAGNOSTICS</td>
<td>+6.7%</td>
</tr>
<tr>
<td>MEDICAL DEVICES</td>
<td>+9.6%</td>
</tr>
<tr>
<td>NUTRITION</td>
<td>+2.0%</td>
</tr>
<tr>
<td>ESTABLISHED PHARMACEUTICALS</td>
<td>+14.0%</td>
</tr>
</tbody>
</table>

**FULL-YEAR 2018 GUIDANCE**

$2.80 TO $2.90 ADJUSTED EPS, MIDPOINT REFLECTS 14% GROWTH.

---

**Life-Changing HEALTH TECHNOLOGY**

**MORE THAN 20 NEW PRODUCTS LAUNCHED IN 2017**

**FREESTYLE® LIBRE**

Launched in the U.S.  
This revolutionary glucose monitoring system eliminates routine fingersticks for people with diabetes and is now approved for coverage by the U.S. Center for Medicare & Medicaid Services.

---

**CONFIRM RX™ INSERTABLE CARDIAC MONITOR (ICM)**

Launched in U.S. & Europe  
The first and only smartphone compatible ICM helps physicians remotely diagnose and treat difficult to detect irregular heartbeats.

---

**ALINITY™**

FDA Clearance for CI-Series  
The game-changing family of diagnostics systems stand to change the way labs work to deliver results that drive better patient outcomes.

---

**XIENCE SIERRA™**

Approved in Europe  
The newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

---

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.